Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

LUMO 10.30.2024

Full Press ReleaseSEC FilingsOur LUMO Tweets

About Gravity Analytica

Recent News

  • 12.12.2024 - Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

Recent Filings

  • 12.23.2024 - 15-12G Securities registration termination [Section 12(g)]
  • 12.13.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.13.2024 - AW Amendment Withdrawal Request
PDF Version

AUSTIN, Texas,Oct. 30, 2024(GLOBE NEWSWIRE) --Lumos Pharma(NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the62nd AnnualEuropean Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be heldNovember 16-18, 2024inLiverpool, UK.

Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented onSunday, November 17th, byElżbieta Petriczko, MD, PhD,Pomeranian Medical University, Szczecin,Poland, and onMonday, November 18th, byPeter E. Clayton, MD,University of Manchester,Manchester, UK, respectively.

LUM-201 Oral Abstract Presentations:

Sunday, November 17th– Session:Free Communications7: GH and IGFs –10:50AMLocal Time

  • FC7.6 Abstract entitled,Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment(Elżbieta Petriczko, MD, PhD,et al)

Monday, November 18th– Session:Free Communications15: Late Breaking –9:40AMLocal Time

  • FC15.2 Abstract entitled,Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD)(Peter E. Clayton, MD,et al)

AboutLumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visithttps://lumos-pharma.com/.

Investor & Media Contact:

Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com

Source:Lumos Pharma, Inc.

Primary Logo

Source: Lumos Pharma, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com